<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589027</url>
  </required_header>
  <id_info>
    <org_study_id>PK22</org_study_id>
    <nct_id>NCT03589027</nct_id>
  </id_info>
  <brief_title>Darunavir and Rilpivirine Interactions With Levonorgestrel Implant</brief_title>
  <acronym>DRIVE-2</acronym>
  <official_title>A Pharmacokinetic Evaluation of Levonorgestrel Implant in HIV-Infected Women on Darunavir Versus Rilpivirine-based Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetic properties of Rilpivirine and Darunavir when
      used in combination with Levonorgestrel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the benefits of hormonal contraceptives, significant drug-drug interactions (DDIs)
      with some antiretroviral therapies (ART) represent a barrier to effective family planning
      methods for HIV-infected women. It is therefore critical to generate data on the combined use
      of hormonal contraceptives and ART. This study is a prospective, non-randomized, open-label,
      parallel, two-group, sparse-sampling pharmacokinetic (PK) study to describe levonorgestrel
      (LNG) PK parameters in two treatment groups (rilpivirine or darunavir- based ART) in 60 HIV-1
      infected women. The primary endpoint is the comparison of the mean LNG concentrations at
      month 6 between the rilpivirine or darunavir treatment groups versus historical controls.
      This study will provide information on effective ART options for HIV positive women who opt
      for the contraceptive implant as a family planning method of choice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, non-randomized, open-label, parallel, two-group, sparse-sampling pharmacokinetic (PK) study to describe levonorgestrel (LNG) PK parameters in two treatment groups (Rilpivirine or Darunavir- based ART) in 60 HIV-1 infected women.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levonorgestrel concentrations: Change in mean levonorgestrel (LNG) concentrations</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the mean levonorgestrel (LNG) concentrations at month 6 between the rilpivirine (RPV) or darunavir (DRV) treatment groups versus historical controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean rilpivirine concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Rilpivirine mean concentration change prior to implant placement and then over the duration of the study time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean darunavir concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Darunavir mean concentration change prior to implant placement and then over the duration of the study time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Any signs and symptoms related to hormone exposure, including abnormal vaginal bleeding and local or systemic adverse events observed during the study period in both study groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Rilpivirine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel two rod sub-dermal implant</intervention_name>
    <description>Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally</description>
    <arm_group_label>Darunavir arm</arm_group_label>
    <arm_group_label>Rilpivirine arm</arm_group_label>
    <other_name>Levonorgestrel</other_name>
    <other_name>Jadelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilpivirine</intervention_name>
    <description>Oral ripilvirine 25mg once daily</description>
    <arm_group_label>Rilpivirine arm</arm_group_label>
    <other_name>Edurant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir+Ritonavir</intervention_name>
    <description>Oral DRV/r 600/100mg twice daily</description>
    <arm_group_label>Darunavir arm</arm_group_label>
    <other_name>DRV/r</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Evidence of a personally signed and dated informed consent document indicating that
             the participant has been informed of all pertinent aspects of the study.

          2. Participants who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

          3. Women age 18 years to 45 years

          4. Diagnosed with HIV infection

          5. Medically eligible for the LNG subdermal implant as a contraceptive method based on
             the WHO Medical Eligibility Criteria for Contraceptive Use11

          6. Receiving EFV- or LPV/r-based ART for a minimum of 1 year

          7. If not abstinent, must agree to use an effective non-hormonal method of contraception
             for the duration of the study including male and female condoms or the copper-T
             intrauterine device.

          8. Participants must have a negative urine pregnancy test at entry and report no
             unprotected sex since the last menstrual period or in the last two weeks.

             -

        Exclusion Criteria:

          1. HIV RNA greater than 50 copies/mL at the screening visit

          2. CD4 count below 200 cells/mm3 at the screening visit

          3. History of virologic failure on the current regimen (two consecutive viral load
             results equal to or greater than 400 copies/mL)

          4. Serum hemoglobin less than 9.0 g/dl at screening

          5. Elevations in serum levels of alanine transaminase (ALT) above 5 times the upper limit
             of normal

          6. Elevations in serum creatinine above 2.5 times the upper limit of normal

          7. Use of drugs known to be contraindicated with LNG, RPV (for women taking EFV-based
             ART), or DRV (for women taking LPV-based ART) within 30 days of study entry. Due to
             the dynamic nature of drug interactions related to antiretroviral therapy, the study
             team will review all concomitant medications at screening based on the US Department
             of Health and Human Services drug interaction table 14 and the University of Liverpool
             HIV drug interaction tables (www.hiv-druginteractions.org)

          8. Currently pregnant or postpartum &lt;30 days at study entry.

          9. Breastfeeding women within 6 months of delivery.

         10. Patients with a history of hypersensitivity to LNG implant, undiagnosed vaginal
             bleeding, diagnosed or suspected sex hormone dependent neoplasia, benign or malignant
             liver tumor, or thromboembolic disease.

         11. Presence of any active clinically significant disease or life-threatening disease
             that, in the investigator's opinion, would compromise the subject's safety or outcome
             of the study.

             -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Lamorde, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior Research Manager</last_name>
    <phone>0704817590</phone>
    <email>sokoboi@idi.co.ug</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infectious Diseases Institue</name>
      <address>
        <city>Kampala</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Research Manager</last_name>
      <phone>0392878652</phone>
      <email>sokoboi@idi.co.ug</email>
    </contact>
    <investigator>
      <last_name>Mohammed Lamorde, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberley Scarsi, PharmD,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Chappell, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saye Khoo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Byakika, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Darin, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shadia Nakalema, MBChB, DTM&amp;H</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Walimbwa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Kaboggoza, BPharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>Infectious Diseases Institute</investigator_full_name>
    <investigator_title>Head of Department, Prevention Care and Treatment Infectious Diseases Institute, Makerere University College of Health Sciences</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

